1. Inicio
  2. Publicaciones
  3. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Berard, Emilie
  • Rollig, Christoph
  • Bertoli, Sarah
  • Pigneux, Arnaud
  • Tavitian, Suzanne
  • Kramer, Michael
  • Serve, Hubert
  • Bornhauser, Martin
  • Platzbecker, Uwe
  • Müller-Tidow C
  • Baldus, Claudia D.
  • Serrano, Josefina
  • Martinez-Sanchez, Pilar
  • Arbolí ER
  • Gil, Cristina
  • Bergua, Juan
  • Bernal, Teresa
  • de la Fuente Burguera, Adolfo
  • Delabesse, Eric
  • Bidet, Audrey
  • Dumas, Pierre-Yves
  • Recher, Christian

Grupos

Abstract

In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival. Here, the data from three European registries for 1,199 AML patients aged 70 years or older treated with intensive chemotherapy were used to develop a prognostic scoring system. The median follow-up was 50.8 months. In the training set of 636 patients, age, performance status, secondary AML, leukocytosis, and cytogenetics, as well as NPM1 mutations (without FLT3-ITD), were all significantly associated with overall survival, albeit not to the same degree. These factors were used to develop a score that predicts long-term overall survival. Three risk-groups were identified: a lower, intermediate and higher-risk score with predicted 5-year overall survival (OS) probabilities of >= 12% (n = 283, 51%; median OS = 18 months), 3-12% (n = 226, 41%; median OS = 9 months) and <3% (n = 47, 8%; median OS = 3 months), respectively. This scoring system was also significantly associated with complete remission, early death and relapse-free survival; performed similarly in the external validation cohort (n = 563) and showed a lower false-positive rate than previously published scores. The European Scoring System >= 70, easy for routine calculation, predicts long-term survival in older AML patients considered for intensive chemotherapy.

© 2022. The Author(s).

Datos de la publicación

ISSN/ISSNe:
2044-5385, 2044-5385

Blood Cancer Journal  SPRINGERNATURE

Tipo:
Article
Páginas:
107-107
PubMed:
35821023
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
3,221 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 11

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • ACUTE MYELOID-LEUKEMIA; ELDERLY-PATIENTS; EARLY DEATH; VENETOCLAX; SURVIVAL; AZACITIDINE; PREDICTION; MANAGEMENT; MUTATIONS; MODEL

Campos de Estudio

Compartir